Streetbeat News

Analyst Ratings

TCBX

Stephens & Co. analyst Matt Olney maintains an Overweight rating on Third Coast Bancshares (NASDAQ:TCBX) and raises the price target from $19 to $24.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:56 pm

BIIB

DSGN

LRMR

RETA

SLDB

Biogen Inc has agreed to acquire Reata Pharmaceuticals Inc for $172.50 per share in cash, reflecting an enterprise value of approximately $7.3 billion. Analysts from William Blair view the acquisition as fitting Biogen's acquisition goals of de-risked, value-added and accretive assets. They also acknowledged potential competition from other clinical-stage programs, including Larimar Therapeutics Inc, Design Therapeutics Inc, and Solid Biosciences Inc. The deal, if finalized in Q4, would consume the majority of Biogen's $10 billion allocation for corporate acquisitions.

Portfolio Pulse from Vandana Singh

July 28, 2023 | 3:56 pm

SQ

Exane BNP has upgraded Block's stock from Underperform to Outperform and set a new price target of $95. This has led to an increase in the trading of Block shares.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 3:55 pm

BMY

Wells Fargo analyst Mohit Bansal has maintained an Equal-Weight rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $78 to $65.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 3:55 pm

SLM

Stephens & Co. analyst Vincent Caintic maintains an Equal-Weight rating on SLM (NASDAQ:SLM) and raises the price target from $15 to $17.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:54 pm

RCL

Wells Fargo analyst Daniel Politzer maintains an Overweight rating on Royal Caribbean Gr (NYSE:RCL) and raises the price target from $109 to $127.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 3:52 pm

MITT

JonesTrading analyst Matthew Erdner has reiterated a 'Buy' rating on AG Mortgage IT (NYSE:MITT) and maintained an $8 price target.

Portfolio Pulse from Benzinga Newsdesk

July 28, 2023 | 3:52 pm

FBMS

Stephens & Co. analyst Matt Olney maintains an Overweight rating on First Bancshares (NASDAQ:FBMS) and raises the price target from $32 to $38.

Portfolio Pulse from jenniferd'souza@benzinga.com

July 28, 2023 | 3:52 pm

LHX

Wells Fargo analyst Matthew Akers has maintained an Equal-Weight rating on L3Harris Technologies (NYSE:LHX) and raised the price target from $202 to $204.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 3:51 pm

NVCR

Wells Fargo analyst Larry Biegelsen has maintained an Overweight rating on NovoCure (NASDAQ:NVCR) but lowered the price target from $104 to $102.

Portfolio Pulse from richadhand@benzinga.com

July 28, 2023 | 3:50 pm